Tillman Gerngross (Adagio)

Till­man Gern­gross' Covid-19 an­ti­body moon­shot scores $336M with the help of new ace CFO. Is an IPO next?

Less than a year in­to its ex­is­tence, se­r­i­al biotech en­tre­pre­neur Till­man Gern­gross’ an­ti­body play Ada­gio has raced ahead in­to a piv­otal tri­al for its lead …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.